Scalable Multiplexed Drug-Combination Screening Platforms Using 3D Microtumor Model for Precision Medicine.
暂无分享,去创建一个
Euisik Yoon | Lili Chen | Yu-Chih Chen | Zhixiong Zhang | Sumithra Urs | Diane M Simeone | E. Yoon | Yu-Chih Chen | Zhixiong Zhang | D. Simeone | S. Urs | Lili Chen
[1] L. Pusztai,et al. Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.
[2] D. Huh,et al. Organs-on-chips at the frontiers of drug discovery , 2015, Nature Reviews Drug Discovery.
[3] John C. Boik,et al. Quantifying synergism/antagonism using nonlinear mixed‐effects modeling: A simulation study , 2008, Statistics in medicine.
[4] Deok-Ho Kim,et al. Microfluidics-assisted in vitro drug screening and carrier production. , 2013, Advanced drug delivery reviews.
[5] Anna Carbone,et al. Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line capan-2 , 2006, Cancer biology & therapy.
[6] A. Jayaraman,et al. A programmable microfluidic cell array for combinatorial drug screening. , 2012, Lab on a chip.
[7] Georges Noel,et al. Three-Dimensional Cell Culture: A Breakthrough in Vivo , 2015, International journal of molecular sciences.
[8] Thomas M. Gress,et al. DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma , 2016, BMC Cancer.
[9] Sangeeta N Bhatia,et al. Engineering protein and cell adhesivity using PEO-terminated triblock polymers. , 2002, Journal of biomedical materials research.
[10] Laurie Thomas,et al. Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer , 2007, Cancer journal.
[11] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[12] Ben Lehner. Genotype to phenotype: lessons from model organisms for human genetics , 2013, Nature Reviews Genetics.
[13] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[14] Lackner,et al. The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy , 2016, Clinical and translational science.
[15] Y F Hui,et al. Gemcitabine: a cytidine analogue active against solid tumors. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[16] D. Yardley,et al. Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes , 2013, International journal of breast cancer.
[17] R C Young,et al. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer , 1975, Cancer.
[18] B. Al-Lazikani,et al. Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.
[19] Sam Michael,et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.
[20] Yong Xu,et al. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. , 2014, Advanced drug delivery reviews.
[21] Andrea Sottoriva,et al. Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine , 2016, Trends in cancer.
[22] Sam Michael,et al. A robotic platform for quantitative high-throughput screening. , 2008, Assay and drug development technologies.
[23] Tao Xu,et al. Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..
[24] Mickael Guedj,et al. Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.
[25] Marilena Loizidou,et al. 3D tumour models: novel in vitro approaches to cancer studies , 2011, Journal of Cell Communication and Signaling.
[26] A. Lipton,et al. Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer , 2010, Journal of clinical gastroenterology.
[27] Julia Schüler,et al. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. , 2014, Urologic oncology.
[28] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[29] M. Clarke,et al. Identification of pancreatic cancer stem cells. , 2007, Cancer research.
[30] N. Mortensen,et al. Reexamination of Hagen-Poiseuille flow: shape dependence of the hydraulic resistance in microchannels. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.
[31] Paul S Mischel,et al. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. , 2013, Carcinogenesis.
[32] E. V. Van Allen,et al. Next-generation sequencing to guide cancer therapy , 2015, Genome Medicine.
[33] Xia Lou,et al. High-Throughput Cancer Cell Sphere Formation for Characterizing the Efficacy of Photo Dynamic Therapy in 3D Cell Cultures , 2015, Scientific Reports.
[34] B. Al-Lazikani,et al. Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance , 2012, Clinical pharmacology and therapeutics.
[35] Seyed Ali Mousavi Shaegh,et al. Microfluidics for Advanced Drug Delivery Systems , 2015, Current opinion in chemical engineering.
[36] Anna Jagusiak,et al. Molecular Dynamics Study of Cisplatin Release from Carbon Nanotubes Capped by Magnetic Nanoparticles , 2013 .
[37] S. Loi,et al. Precision medicine for metastatic breast cancer—limitations and solutions , 2015, Nature Reviews Clinical Oncology.
[38] Wei Zheng,et al. Phenotypic screens as a renewed approach for drug discovery. , 2013, Drug discovery today.
[39] Zhixiong Zhang,et al. Microfluidics 3D gel-island chip for single cell isolation and lineage-dependent drug responses study. , 2016, Lab on a chip.
[40] D. Bojanic,et al. Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.
[41] Ying Zhu,et al. Cell-based drug combination screening with a microfluidic droplet array system. , 2013, Analytical chemistry.
[42] Kwangmi Kim,et al. Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells , 2014, Biomolecules & therapeutics.
[43] Se-Kwon Kim,et al. Log-scale dose response of inhibitors on a chip. , 2011, Analytical chemistry.
[44] L. Panasci,et al. Chemotherapy for advanced pancreatic cancer. A comparison of 5‐fluorouracil, adriamycin, and mitomycin (fam) with 5‐fluorouracil, streptozotocin, and mitomycin (fsm) , 1986, Cancer.
[45] Zhixiong Zhang,et al. Single cell dual adherent-suspension co-culture micro-environment for studying tumor-stromal interactions with functionally selected cancer stem-like cells. , 2016, Lab on a chip.
[46] R. K. Mehmood,et al. Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibody Treatments , 2014, Oncology reviews.
[47] John G. Moffat,et al. Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.
[48] B. Chung,et al. Human neural stem cell growth and differentiation in a gradient-generating microfluidic device. , 2005, Lab on a chip.